Loading…
Reported covered position: Dpty Comm, Pol, Leg, Intnl Affrs, FDA, Mar19Jan21; Mar17Mar19; Spcl Asst HHS, Jan21Mar17; Dec09Jan21; Hlth Dirctr, Sen Burr, Sen Hlth, L&P Comm, Apr09Dec09; Stff Mbr, Sen VA Comm, Feb09Apr09; AsstDrctr, WH Jan0709; LA, LC, SA, SenSantorum, May03Dec06
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to distributor-supported service models and related policy, including pharmacy services administrative organizations and management services organizations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Source: Senate LDA
| ALKEUS PHARMACEUTICALS, INC. |
| 8 |
| 2024–2025 |
| ALLIANCE FOR AGING RESEARCH | 8 | 2024–2025 |
| CHATTEM, INC. DBA OPELLA | 8 | 2025–2026 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | 7 | 2021–2023 |
| ABIOMED, INC. | 5 | 2021–2022 |
| BIOSPLICE THERAPEUTICS, INC. | 5 | 2025–2026 |
| CELLDEX THERAPEUTICS, INC. | 5 | 2025–2026 |
| KYVERNA THERAPEUTICS, INC. | 5 | 2025–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 5 | 2022–2023 |
| FLORIDA CITRUS MUTUAL | 4 | 2021–2025 |
| FUJIFILM HOLDINGS AMERICA CORPORATION | 4 | 2023–2024 |
| WW International, Inc. | 4 | 2025–2026 |
| CENTRIENT PHARMACEUTICALS LLC | 3 | 2021–2022 |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | 3 | 2025–2026 |
| AIR EVAC LIFETEAM | 2 | 2021 |
| FLETCHER GROUP INC. | 2 | 2025 |
| GOJO INDUSTRIES | 2 | 2021–2022 |
| HEALTHCARE DISTRIBUTION ALLIANCE | 2 | 2026 |
| JUICE PRODUCTS ASSOCIATION, INC. | 2 | 2024–2025 |
| PARTNERSHIP FOR MEDICAID HOME-BASED CARE | 2 | 2024 |
| ABBOTT LABORATORIES | 1 | 2024 |
| AMGEN USA, INC. | 1 | 2024 |
| ILLUMINA, INC. | 1 | 2023 |
| KIMBERLY-CLARK CORPORATION | 1 | 2025 |
| MEDLINE INDUSTRIES, LP | 1 | 2025 |
| ResMed Corp. | 1 | 2026 |
| U.S. CHAMBER OF COMMERCE INSTITUTE FOR LEGAL REFORM | 1 | 2024 |
| UNIVERSITY OF LOUISVILLE | 1 | 2023 |
| ZELIS HEALTHCARE CORPORATION | 1 | 2024 |
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
State of Men’s Health Act
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Financial Services and General Government Appropriations Act, 2027
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Financial Services and General Government Appropriations Act, 2027
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status; Issues related to consumer health care products supply chain; Issues related to FY27 appropriations report language, including H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 and H.R. 8495 - Financial Services and General Government Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BIOSPLICE THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260).
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: KYVERNA THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to developing cell and gene therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646).
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: KYVERNA THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status; Issues related to consumer health care products supply chain; Issues related to FY27 appropriations report language, including H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 and H.R. 8495 - Financial Services and General Government Appropriations Act, 2027.
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BIOSPLICE THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; Issues related to H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75); Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues related to H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75); Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues related to H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services and care coordination; Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BIOSPLICE THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BIOSPLICE THERAPEUTICS, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; Issues related to H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Lower Costs, More Transparency Act of 2026
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Neonatal Care Transparency Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Mikaela Naylon Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Mikaela Naylon Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
State of Men’s Health Act
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to PAHPA reauthorization; Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 1262/S. 932 - Give Kids a Chance Act of 2025).
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025; Issues related to biotechnology innovation ecosystems.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: FLETCHER GROUP, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to substance use disorder; Issues related to recovery housing; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025; Issues related to authorization of the Rural Communities Opioid Response Program.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination and veteran mental health; 988 Suicide and Crisis Lifeline; Issues related to FY26 appropriations bills for Labor-HHS, CJS, Mil-Con-VA; SUPPORT Act reauthorization proposals, including H.R. 2483 - SUPPORT for Patients and Communities Reauthorization Act of 2025.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; 988 Suicide and Crisis Lifeline; Issues related to FY26 appropriations bills for Labor-HHS, CJS, Mil-Con-VA; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025.
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ALLIANCE FOR AGING RESEARCH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to utilization management and changes to Medicare Part D; Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587).
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Issues related to substance use disorder; Issues related to recovery housing; Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to H.R. 6407 - RCORP Authorization Act; Issues related to authorization of the Rural Communities Opioid Response Program.
Defending Domestic Orange Juice Production Act of 2025
Client: FLORIDA CITRUS MUTUAL · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Issues related to the Farm Bill.
Defending Domestic Orange Juice Production Act of 2025
Client: JUICE PRODUCTS ASSOCIATION, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Strategic policy advice related to orange juice standards.
Defending Domestic Orange Juice Production Act of 2025
Client: JUICE PRODUCTS ASSOCIATION, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Strategic policy advice related to orange juice standards.
Defending Domestic Orange Juice Production Act of 2025
Client: FLORIDA CITRUS MUTUAL · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Issues related to the Farm Bill.
MAPS Act
Client: UNITED STATES PHARMACOPEIAL CONVENTION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to advanced manufacturing, drug shortages, and pharmaceutical supply chains; Issues related to S.1784 - MAPS Act.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; 988 Suicide and Crisis Lifeline; Issues related to FY26 appropriations bills for Labor-HHS, CJS, Mil-Con-VA; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: FLETCHER GROUP, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to substance use disorder; Issues related to recovery housing; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025; Issues related to authorization of the Rural Communities Opioid Response Program.
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
SUPPORT for Patients and Communities Reauthorization Act of 2025
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Over-the-Counter Monograph Drug User Fee Amendments
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
Client: CHATTEM, INC. DBA OPELLA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: ALLIANCE FOR AGING RESEARCH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to utilization management and changes to Medicare Part D; Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: QNOVIA, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BAMBOO HEALTH · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025; Issues related to biotechnology innovation ecosystems.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to PAHPA reauthorization; Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 1262/S. 932 - Give Kids a Chance Act of 2025).
Defending Domestic Orange Juice Production Act of 2023
Client: JUICE PRODUCTS ASSOCIATION, INC. · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 1750/S. 103 - Defending Domestic Orange Juice Production Act of 2023.
Drug Shortage Prevention Act of 2023
Client: UNITED STATES PHARMACOPEIAL CONVENTION · Firm: AKIN GUMP STRAUSS HAUER & FELD
PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008 - Drug Shortage Prevention and Mitigation Act; Issues related to drug shortages.
Drug Shortage Prevention Act of 2023
Client: UNITED STATES PHARMACOPEIAL CONVENTION · Firm: AKIN GUMP STRAUSS HAUER & FELD
PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008/S.2363 - Drug Shortage Prevention and Mitigation Act; S.5040 -Protecting Patients from Deceptive Drug Ads Online Act; Issues related to drug shortages.
Issues related to behavioral health services and prescription drug monitoring programs; 988 Suicide and Crisis Lifeline; SUPPORT Act reauthorization proposals, including S.2433 - SUPPORT for Patients and Communities Reauthorization Act of 2023 and H.R.4531 - the Support for Patients and Communities Reauthorization (SUPPORT) Act of 2023; H.R. 4099 - the RECONNECTS Act of 2023; implementation of FY 2024 CJS and Labor-HHS appropriations bills; FY 2025 CJS and Labor-HHS appropriations bills.
Issues related to behavioral health services and prescription drug monitoring programs; SUPPORT Act reauthorization proposals, including S. 3393/S. 3106/S. 2433/H.R. 4531 - the SUPPORT for Patients and Communities Reauthorization Act; H.R. 4099 - the RECONNECTS Act of 2023; FY 2024 and FY 2025 CJS and Labor-HHS appropriations bills.
Issues related to behavioral health services, prescription drug monitoring programs, 988 Suicide and Crisis Lifeline, care coordination and veteran mental health; S.4795 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S.3393 - SUPPORT for Patients and Communities Reauthorization Act; H.R.4531 - Support for Patients and Communities Reauthorization Act; H.R.4099 - RECONNECTIONS Act of 2023; implementation of Fiscal Year CJS and Labor-HHS appropriations.
Protecting Older Americans Act of 2023
Client: U.S. CHAMBER OF COMMERCE INSTITUTE FOR LEGAL REFORM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to legal reform, including arbitration; the FY25 Appropriations legislation and FY25 National Defense Authorization Act; H.R.4120/S.1979 - Protecting Older Americans Act; issues related to third-party litigation funding, including S. 2805/H.R. 5488 - Protecting Our Courts from Foreign Manipulation Act of 2023.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: UNITED STATES PHARMACOPEIAL CONVENTION · Firm: AKIN GUMP STRAUSS HAUER & FELD
PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008 - Drug Shortage Prevention and Mitigation Act; Issues related to drug shortages.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: UNITED STATES PHARMACOPEIAL CONVENTION · Firm: AKIN GUMP STRAUSS HAUER & FELD
PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); Pharmaceutical supply chain issues, S. 2364 - Mapping America's Pharmaceutical Supply Act; S.2589 - Drug Shortage Prevention and Quality Improvement Act.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Pandemic and All-Hazards Preparedness Act (PL 109-417) reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); drug pricing issues; PBM reform (S. 2973 - Modernizing and Ensuring PBM Accountability Act; S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); H.R. 7384/S. 4583 - Rare Pediatric Priority Review Voucher Program reauthorization; S. 2305 - the Biosimilar Red Tape Elimination Act; H.R.5429/S. 2780 - the Medication Affordability and Patent Integrity Act.
Preparing for All Hazards and Pathogens Reauthorization Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - the Preparing for All Hazards and Pathogens Reauthorization Act); Drug pricing issues; PBM reform (S. 2973 -Modernizing and Ensuring PBM Accountability Act and S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 7384/ S. 4583 - Creating Hope Reauthorization Act); National Vaccine Injury Compensation Program.
Issues related to clinical lab billing under OPPS.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to biotech ecosystem; Issues related to PAHPA reauthorization; Issues related to PDUFA reauthorization; Issues related to extending authorization of rare pediatric priority review voucher program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to developing cell and gene therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOSPLICE THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260).
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to behavioral health services, prescription drug monitoring programs, care coordination, including for VA, Medicare and Medicaid beneficiaries, and veteran mental health; Issues related to the 988 Suicide and Crisis Lifeline; Issues related to the Great American Recovery Initiative; Issues related to the final FY26 Labor-HHS Appropriations bill (P.L. 119-75); Issues related to SUPPORT Act reauthorization (including S. 2433, H.R. 4531); Issues related to the RECONNECTIONS Act (within H.R.4531/S. 2433); Issues related to FY27 appropriations and related report language for Labor-HHS and CJS, including Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260) and Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 (H.R. 8845).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues related to Medicare Advantage compensation and agent and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · Q3
Issues regarding smoking cessation.
Filing targets: SENATE
HEALTHCARE DISTRIBUTION ALLIANCE via AKIN GUMP STRAUSS HAUER & FELD
2026 · third_quarter · RR
Issues related to distributor-supported service models and related policy.
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to expanded GLP-1 coverage; Issues related to the implementation of GLP-1 Bridge; Issues related to CMMI ACCESS and BALANCE models; Issues related to the expanded coverage of lifestyle and behavioral support services to achieve healthy outcomes for patients.
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services, including lifestyle and behavioral support services to achieve healthy outcomes for patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
RESMED CORP. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to AI-enabled medical devices, sleep health, and the management and prevention of chronic disease.
Issues related to respiratory, cloud-connected sleep care, and chronic disease prevention in the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), Vice President of the U.S.
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues regarding smoking cessation; Issues related to H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37); Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status; Issues related to consumer health care products supply chain; Issues related to FY27 appropriations report language, including H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 and H.R. 8495 - Financial Services and General Government Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to mast cell conditions and therapies; Issues related to drug development and biopharma ecosystem.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOSPLICE THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; Issues related to H.R.8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027; Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to behavioral health services and care coordination; Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75); Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues related to H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to Medicare Advantage compensation and agent and broker policies; Issues related to MedPAC nominations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to clinical lab billing under OPPS.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · second_quarter · Q2
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services; Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health services within CMMI models to achieve healthy outcomes for patients; Issues related to TrumpRx.
Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health and support services within CMMI models to achieve healthy outcomes for patients; Issues related to TrumpRx.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and Multiple Sclerosis; Issues related to appropriations report language for Fiscal Year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BIOSPLICE THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; Issues related to appropriations report language for Fiscal Year 2027.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to behavioral health services and care coordination (including Medicare and Medicaid); Issues related to Medicare Program policy for Contract Year 2027 and technical changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Proposed Rule; Issues related to Fiscal Year 2027 appropriations report language concerning Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS).
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75); Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to Medicare Program policy for Contract Year 2027 and technical changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Proposed Rule; Issues related to Fiscal Year 2027 appropriations report language concerning Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS), and Commerce, Justice, Science, and Related Agencies (CJS).
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2026 · first_quarter · Q1
Issues related to Medicare Advantage compensation and agent and broker policies; Issues related to MedPAC nominations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to GLP-1 products, including coverage for GLP-1 products and related health services; Issues related to TrumpRx.
Issues related to expanded GLP-1 coverage, including Medicare and Medicaid coverage for GLP-1 products and related health services within CMMI models to achieve healthy outcomes for patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)
FLETCHER GROUP, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to substance use disorder; Issues related to recovery housing; Issues related to the SUPPORT for Patients and Communities Reauthorization Act of 2025 (P.L. 119-44); Issues related to H.R. 6407 - RCORP Authorization Act; Issues related to authorization of the Rural Communities Opioid Response Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025; Issues related to biotechnology innovation ecosystems.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KIMBERLY-CLARK CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to corporate acquisition.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to smoking cessation; Issues related to appropriations bill reports for H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Issues related to the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (P.L. 119-37).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to NIH-funded research; Issues related to mast cell conditions and therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOSPLICE THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 5342/S. 2354 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026; H.R. 3944 - Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026; Reauthorization proposals in H.R. 2483/S. 2121 - The SUPPORT for Patients and Communities Reauthorization Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to Medicare Advantage compensation, agent and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · Q4
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WW INTERNATIONAL, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · RR
Issues related to GLP-1 products, including Medicare and Medicaid coverage or GLP-1 products and related health services.
Issues related to GLP-1 products, including Medicare and Medicaid coverage or GLP-1 products and related health services.
BIOSPLICE THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · RR
Issues related to the development and manufacturing of therapies for osteoarthritis, oncology, and areas of significant unmet medical need.
KYVERNA THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · fourth_quarter · RR
Issues related to developing cell therapies for patients.
FLETCHER GROUP, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to substance use disorder; Issues related to recovery housing; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025; Issues related to authorization of the Rural Communities Opioid Response Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to smoking cessation; Issues related to appropriations bill reports for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (H.R. 4121/S. 2256); Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Issues related to the Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to NIH-funded eosinophilic gastrointestinal disease research; Issues related to mast cell conditions and therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including in Medicare and Medicaid), and veteran mental health; Issues related to 988 Suicide and Crisis Lifeline; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587); Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 (H.R. 5342/S. 2354); Military Construction and Veterans Affairs, Agriculture, and Legislative Branch Appropriations Act, 2026 (H.R. 3944); Reauthorization proposals in The SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R.2483/S. 2121).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to Medicare Advantage compensation, agent and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to utilization management and changes to Medicare Part D; Issues related to the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304/S. 2587).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · third_quarter · Q3
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; H.R. 1262/S. 932 - Give Kids a Chance Act of 2025.
Issues related to the One Big Beautiful Bill Act (P.L. 119-21) Section 44301, expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUICE PRODUCTS ASSOCIATION, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Strategic policy advice related to orange juice standards.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLORIDA CITRUS MUTUAL via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
H.R. 933/S. 1251 - Defending Domestic Orange Juice Production Act of 2025; Issues related to the Farm Bill.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
UNITED STATES PHARMACOPEIAL CONVENTION via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to advanced manufacturing, drug shortages, and pharmaceutical supply chains; Issues related to S.1784 - MAPS Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues regarding smoking cessation; Issues regarding FY26 appropriations bill reports for Labor-HHS and Ag-FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to NIH-funded eosinophilic gastrointestinal disease research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to behavioral health services, prescription drug monitoring programs, care coordination (including Medicare and Medicaid), and veteran mental health; 988 Suicide and Crisis Lifeline; Issues related to FY26 appropriations bills for Labor-HHS, CJS, Mil-Con-VA; Issues related to H.R. 2483/S. 2121 - SUPPORT for Patients and Communities Reauthorization Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to Medicare Advantage compensation, agent and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to utilization management and changes to Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · second_quarter · Q2
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDLINE INDUSTRIES, LP via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to trade.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to cancer screening, testing, and the Calendar Year 2026 Physician Fee Schedule Rule.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to PAHPA reauthorization; Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 1262/S. 932 - Give Kids a Chance Act of 2025).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED STATES PHARMACOPEIAL CONVENTION via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to the Pandemic and All-Hazards Preparedness Act (P.L. 109-417)(PAHPA) reauthorization; Issues related to the pharmaceutical supply chain, drug shortages, advanced manufacturing, and pharmaceutical standards.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues regarding smoking cessation; FY26 appropriations bill reports for Labor-HHS and Ag-FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to behavioral health services, prescription drug monitoring programs, care coordination and veteran mental health; 988 Suicide and Crisis Lifeline; Issues related to FY26 appropriations bills for Labor-HHS, CJS, Mil-Con-VA; SUPPORT Act reauthorization proposals, including H.R. 2483 - SUPPORT for Patients and Communities Reauthorization Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues pertaining to Medicare Advantage compensation, agent and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to utilization management and changes to Medicare Part D.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · Q1
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLDEX THERAPEUTICS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · RR
Issues related to biotechnology policy.
CHATTEM, INC. DBA OPELLA via AKIN GUMP STRAUSS HAUER & FELD
2025 · first_quarter · RR
Issues related to non-prescription drug and dietary supplement policy.
UNITED STATES PHARMACOPEIAL CONVENTION via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008 - Drug Shortage Prevention and Mitigation Act; Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JUICE PRODUCTS ASSOCIATION, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
H.R. 1750/S. 103 - Defending Domestic Orange Juice Production Act of 2023.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to infant formula liability reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues regarding smoking cessation; H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.9027/S.4690 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to behavioral health services, prescription drug monitoring programs, 988 Suicide and Crisis Lifeline, care coordination and veteran mental health; S.4795 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S.3393 - SUPPORT for Patients and Communities Reauthorization Act; H.R.4531 - Support for Patients and Communities Reauthorization Act; H.R.4099 - RECONNECTIONS Act of 2023; implementation of Fiscal Year CJS and Labor-HHS appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues pertaining to Medicare Advantage compensation, agent, and broker policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to utilization management and changes to Medicare Part D.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to cancer care and treatment; medical device remanufacturing; AI use in health care; potential medical isotope shortage.
Issues related to medical device remanufacturing.
Issues related to medical device remanufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2024 · fourth_quarter · Q4
PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - the Preparing for All Hazards and Pathogens Reauthorization Act); Drug pricing issues; PBM reform (S. 2973 -Modernizing and Ensuring PBM Accountability Act and S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); Rare Pediatric Disease Priority Review Voucher Program reauthorization (H.R. 7384/ S. 4583 - Creating Hope Reauthorization Act); National Vaccine Injury Compensation Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. CHAMBER OF COMMERCE INSTITUTE FOR LEGAL REFORM via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to legal reform, including arbitration; the FY25 Appropriations legislation and FY25 National Defense Authorization Act; H.R.4120/S.1979 - Protecting Older Americans Act; issues related to third-party litigation funding, including S. 2805/H.R. 5488 - Protecting Our Courts from Foreign Manipulation Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to cancer care and treatment; medical device remanufacturing; AI use in health care; potential medical isotope shortage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Pandemic and All-Hazards Preparedness Act (PL 109-417) reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); drug pricing issues; PBM reform (S. 2973 - Modernizing and Ensuring PBM Accountability Act; S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); H.R. 7384/S. 4583 - Rare Pediatric Priority Review Voucher Program reauthorization; S. 2305 - the Biosimilar Red Tape Elimination Act; H.R.5429/S. 2780 - the Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED STATES PHARMACOPEIAL CONVENTION via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
PAHPA reauthorization, including S.2333 - the Pandemic and All-Hazards Preparedness and Response Act and H.R.4421 - Preparing for All Hazards and Pathogens Reauthorization Act; Pharmaceutical supply chain issues; H.R.6992/S.2364 - MAPS Act; H.R.3008/S.2363 - Drug Shortage Prevention and Mitigation Act; S.5040 -Protecting Patients from Deceptive Drug Ads Online Act; Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues regarding smoking cessation; H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.9027/S.4690 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARTNERSHIP FOR MEDICAID HOME-BASED CARE via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to home and community-based services; H.R.8114 - To prohibit the Secretary of Health and Human Services from finalizing a rule proposed by the Centers for Medicare & Medicaid Services to place certain limitations on Medicaid payments for home or community-based services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FUJIFILM HOLDINGS AMERICA CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to domestic pharmaceutical manufacturing; S.2333 - Pandemic and All-Hazards Preparedness and Response Act reauthorization; S.3558 - Prohibiting Foreign Access to American Genetic Information Act of 2024; H.R. 8333 - BIOSECURE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAMBOO HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to behavioral health services, prescription drug monitoring programs, 988 Suicide and Crisis Lifeline, care coordination and veteran mental health; S.4795 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S.3393 - SUPPORT for Patients and Communities Reauthorization Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
AMERILIFE GROUP, LLC via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues pertaining to Medicare Advantage compensation policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR AGING RESEARCH via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to utilization management and changes to Medicare Part D, aging issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKEUS PHARMACEUTICALS, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · third_quarter · Q3
Issues related to Stargardt disease and rare disease therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNITED STATES PHARMACOPEIAL CONVENTION via AKIN GUMP STRAUSS HAUER & FELD
2024 · second_quarter · Q2
PAHPA reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); Pharmaceutical supply chain issues, S. 2364 - Mapping America's Pharmaceutical Supply Act; S.2589 - Drug Shortage Prevention and Quality Improvement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2024 · second_quarter · Q2
Issues related to cancer care and treatment; medical device remanufacturing; AI use in health care; potential medical isotope shortage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via AKIN GUMP STRAUSS HAUER & FELD
2024 · second_quarter · Q2
Pandemic and All-Hazards Preparedness Act (PL 109-417) reauthorization (S. 2333 - Pandemic and All-Hazards Preparedness and Response Act; H.R. 4421 - Preparing for All Hazards and Pathogens Reauthorization Act); drug pricing issues; PBM reform (S. 2973 - Modernizing and Ensuring PBM Accountability Act; S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023); H.R. 7384/S. 4583 - Rare Pediatric Priority Review Voucher Program reauthorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QNOVIA, INC. via AKIN GUMP STRAUSS HAUER & FELD
2024 · second_quarter · Q2
Issues regarding smoking cessation; H.R. 4534 - the Women and Lung Cancer Research and Preventive Services Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE